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FOREWORD 
The Scientific Committee on AnimaL Nutrition was set up by Commission 
Decision 76/791/EEC of 24 September 1976 (1) in order to provide the 
Commission with informed opinions on scientific matters relating to the 
use of feed additives. The members of the Scientific Committee are 
independent and highly qualified scientists in the relevant fields of 
veterinary and human medicine, animal nutrition and environmental 
protection. The Secretariat of the Committee is provided by the 
Commission's Directorate-General for Agriculture. 
The seventh series of reports of the Scientific Committee for Animal 
Nutrition (2) contains the opinions expressed by the Committee during 
the years 1987 and 1988 in answer to the questions of the Commission. 
They developed as the result of intensive discussions of the members of 
the Committee and reflect the present state of knowledge concerning the 
feed additives to be judged as well as the provisions of the relevant 
Community legislation, in particular the requirements of Council 
Directive 84/587/EEC of 29 November 1984 (3) amending Directive 
70/524/EEC of 23 November 1970 concerning additives in feedingstuffs (4) 
and of the Council Directive 87/153/EEC of 16 February 1987 fixing 
guidelines for the assessment of additives in animal nutrition (5). 
(1) O.J. No L 279 of 9.10.1976, p. 35 
(2) Previous series were published by the Office for Official 
Publications of the European Communities, Luxemburg, as follows 
1st series 
2nd series 
3rd series 
4th series 
5th series 
6th series 
(1979) 
(1980) 
(1981) 
(1984) 
(1986) 
(1987) 
: 
3 
: 
: 
: 
: 
Catalogue No CB-28-79-277 
No EUR 6918 
No EUR 7383 ' 
No EUR 8769 
No EUR 10410 
No EUR 10996 
(3) O.J. No L 319, 8.12.1984, p. 13 
(4) O.J. No L 270, 14.12.1970, p. 1 
(5) O.J. No L 64, 7. 3.1987, p. 19 
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REPORT OF THE SCIENTIFIC COMMITTEE FOR ANIMAL NUTRITION 
ON THE USE OF MADURAMICIN AMMONIUM IN 
FEEDINGSTUFFS FOR CHICKENS FOR FATTENING 
Opinion expressed 27 April 1988 
TERMS OF REFERENCE (October 1986) 
The Scientific Committee for Animal Nutrition is requested to give an 
opinion on the following questions: 
1. Has the use as coccidiostat of the antibiotic maduramicin ammonium 
(ammonium salt of polyether monocarboxylic acid) at the dosage 
proposed for chickens for fattening (see background) significant 
effects on the prevention of coccidiosis in this animal species? 
2. Is this use safe for chicken? 
3. Can it result in the development of resistance in bacteria to 
prophylactic or therapeutic preparations? 
4. What is the metabolic rate of maduramicin in the chicken? Does the 
proposed use result in residues in animal tissues? If so, what are 
the qualitative and quantitative composition and persistence of these 
residues? 
5. Do the toxicological studies allow to conclude that the proposed use 
does not present risks 
- for the consumer? 
- for the user? 
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6. What are the nature and the persistence of excreted products derived 
from maduramicin ammonium? Can these products be prejudicial to the 
environment? 
7. In the light of the answers to the above questions, are the proposed 
conditions of use acceptable? 
BACKGROUND 
Maduramicin ammonium was the subject of an application for admission in 
Section D (Coccidiostats and other medicinal substances) of the Annex to 
Council Directive 70/524/EEC, of 23 November 1970, concerning additives 
in feedingstuffs(l) under the following conditions of use: 
Species of animal : chickens for fattening 
Use level : 5 mg/kg complete feedingstuff 
Other provisions : use prohibited at least five days before slaughter. 
OPINION OF THE COMMITTEE 
1. Maduramicin ammonium is an ionophore consisting of 90% of the ammonium 
salt of a polyether monocarboxylic acid with an 0CH3 group at the C5 
of the A ring (alpha-maduramicin) and 10% of the structurally similar 
compound with an -OH group instead of -0CH3 at the C5 of the A ring 
(beta-maduramicin). The efficacy of maduramicin as a coccidiostat in 
chickens for fattening has been tested in battery chickens for 
fattening infected with four laboratory strains of Eimeria and in 
pen-raised chickens for fattening infected with six field strains of 
Eimeria. These trials established an effective but narrow dose range 
of 5-6 mg/kg complete feedingstuff as judged by improved weight gain, 
improved feed efficiency, reduced number of gut lesions and reduced 
mortality. 
(1) O.J. No L 270 of 14.12.1970, p.l 
In battery trials in six countries 5 mg/kg complete feedingstuff was 
effective in preventing clinical coccidiosis and was comparable to 
treatment with other ionophores. A similar series of pen-raised 
chickens for fattening in seven countries confirmed the efficacy of 
that dosage regime when judged by similar parameters. In trials under 
commercial conditions in seven countries involving 3,25 million 
chickens for fattening 5 mg/kg complete feedingstuff was efficacious 
while higher levels caused a reduction in body weight gain. 
These findings suggest that maduramicin is effective for the 
prevention of clinical coccidiosis in chickens for fattening at a dose 
of 5 mg/kg complete feedingstuff. 
Administration of maduramicin to chickens for fattening at doses as 
high as 15 mg/kg feedingstuff resulted in significant depression of 
body weight gain. Feed efficiency was reduced at doses from 
8-15 mg/kg feedingstuff. No other treatment-related effects were 
noted except a slight reduction in lymphoid tissue of the bursa and 
thymus at high doses. 
Maduramicin had no adverse effects at 5 mg/kg feed on turkey poults, 
guinea fowl, laying turkeys, fattening rabbits, horses, grower and 
finishing pigs, lactating cows and finishing steers. Maduramicin has 
no deleterious effect on carcase quality and flavour in chickens for 
fattening. 
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3. Maduramicin ammonium is an ionophore antibiotic with moderate activity 
against many Gram-positive bacteria, but with no activity against 
Gram-negative organisms. Although no in vitro studies on the 
development of resistance and cross resistance were carried out, the 
in vivo studies showed that stable resistance caused by chromosomal 
mutation in sensitive Gram-positive organisms does not develop, even 
though a transient loss in sensitivity was observed. Maduramicin does 
not cause the selection of transmissible resistance factors in 
indigenous faecal coliforms nor in experimentally introduced 
salmonella. No effect was observed on colonisation or shedding of 
salmonella in chickens. 
The addition of maduramicin ammonium at the proposed dose of 5 mg/kg 
complete feedingstuff to the feed of chickens does not lead to the 
development of bacterial resistance to prophylactic or therapeutic 
preparations nor does it cause a persistence of Gram-negative bacteria 
in the gut of chickens. 
4. The metabolism of maduramicin was studied using the compound labelled 
with 14-C in 7 well defined positions in the molecule. Rats 
metabolise alpha-maduramicin by O-demethylation at a site in the 
terminal G ring, the metabolite in the chicken being 
beta-maduramicin. The liver is the main site of metabolism in the rat 
and the other species. In the rat 96% of the radioactivity was 
extracted and consisted of 36% alpha-maduramicin and 64% metabolites. 
Maduramicin and/or its metabolites are rapidly eliminated, more than 
70% of the ingested radioactivity being recovered in the excreta 
within the first 48 hours and more than 93% within the first 5 days of 
withdrawal. No measurable radioactivity was found in the carcase 
after 8 days withdrawal. Repeated administration leads to a 
steady-state plasma level after 72h. Detailed tissue level kinetics 
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have not been determined. However at zero withdrawal time residues 
are found mainly in fat and skin (1,29 mg/kg tissue), liver 
(0,49 mg/kg tissue) and kidneys (0,13 mg/kg de tissue), with very 
little appearing in muscle (0,05 mg/kg tissue). These tissue levels 
decreased rapidly to the limit of detection (0,025 mg/kg) in muscle 
(1 day), but more slowly in kidneys (3 days), skin (4 days), liver 
(5 days) and fat (7 days). The residue half-life was 20-27 hours. 
Tissue residues in chickens fed 5 mg/kg feed for 29 to 44 days, are 
measured by RIA (detection limit 0,025 mg/kg), closely correlated with 
the radiochemical estimates but were generally somewhat lower. 
Overall no significant residues were detectable by RIA 
(Radioimmunoassay) after 5 days withdrawal. 
Of the tissue metabolites in chickens dosed with 5,5 mg/kg 14-C 
maduramicin in feed for 7 days, 93-99% were extractable. Most was 
alpha-maduramicin, the balance being beta-maduramicin. No other 
metabolites were detected. 
The antibiotic activity of the residues in tissues was not determined 
but in the fat it would be essentially that of alpha-maduramicin, the 
major component. Roasting of the carcase had no effect on tissue 
residue levels. 
5. Maduramicin has been tested thoroughly in acute toxicity, 28-day, 
90-day and 12-month studies, in carcinogenicity, chronic toxicity, 
reproductive function and teratogenicity studies in mice, rats, 
rabbits and dogs. Mutagenicity was examined both in in vitro and in 
vivo tests. 
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The alpha and beta components had a high acute oral toxicity in the 
mouse and rat and a high dermal toxicity in the rabbit. The 
subchronic studies in the rat and dog showed adverse effects on 
growth, the heart being the target organ in the rat (lowest effective 
dose 0,35 mg/kg body weight), the heart, skeletal muscle and the eye 
being target organs in the dog (lowest effective dose 0,45 mg/kg body 
weight). The rat reproductive studies showed marginal effects on pup 
weight, litter size and pup survival in the F2b generation at 
0,15 mg/kg body weight. Maduramicin is not teratogenic or foetotoxic 
but 3 mg/kg body weight caused 100% maternal mortality. Maduramicin 
is not carcinogenic. The NEL is based on the long-term rat study, 
giving an estimated ADI of 0,001 mg/kg body weight. Maduramicin is 
not genotoxic except for equivocal results in one test for chromosomal 
aberrations in mammalian cells. 
Alpha-maduramicin has a preferential affinity for monovalent cations 
as shown in ion displacement studies (Chao-Min liu et al., 1983). 
Tests in model systems for cardiovascular and central nervous system 
effects, because of the known pharmacological activities of 
ionophores, produced no significant effects. These pharmacological 
studies produced no evidence of myocardial damage in the rat and dog 
except for ECG changes in the dog at very high dose levels (1 mg/kg 
b.w.). Maduramicin has been shown to be incompatible with the 
therapeutic antibiotic tiamulin. 
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Although maduramicin is irritating to the skin and corrosive to the 
eye the method of preparation of the premix prevents any formation of 
dust containing maduramicin. The allergenic potential has not been 
examined. 
On the basis of these findings the Committee concludes, that at the 
doses proposed for use in chickens there is no risk for the consumer 
nor for the user. Intake from residues up to 60 ug/person per day is 
acceptable on the basis of the ADI. 
The half-life of maduramicin in stored chicken excreta, as determined 
by antibiotic activity measurements, is about 55 days depending on the 
temperature of storage. The concentration in the soil following 
standard agricultural practice of fertiliser usage is of the order of 
2-6 ug/kg soil. Further maduramicin is rapidly degraded in the soil 
to a large number of polar breakdown products only 7% remaining as 
maduramicin. Considering these low levels it would be unrealistic to 
require the identification of the degradation products in the soil. 
The toxicity of maduramicin for the Daphnia and fish is similar, the 
NEL being approximately 1 mg/1. Neither methanogenesis nor soil 
nitrification are inhibited by maduramicin in chicken excreta when 
these are used as fertiliser nor does it have any significant 
phytotoxicity. 
In the opinion of the Committee the excreted products derived from 
maduramicin are not prejudicial to the environment. 
7. In the light of the information supplied the Committee is of the 
opinion that maduramicin ammonium is acceptable without risk for use 
in the feedingstuff for chickens for fattening at a level of 5 mg/kg 
complete feedingstuff subject to a withdrawal period of 5 days before 
slaughter. 
References : Dossiers supplied by Cyanamid 
Liu, Chao-Min, Hermann, T.E., Downey, Α., Prosser, B. La T. 
Schildknecht, E., Palleroni, N.J., Westley, J.W. and 
Miller, P.A., J. Antibiotics (1983), 36 (4), 343-350 
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SECOND REPORT OF THE SCIENTIFIC COMMITTEE FOR ANIMAL NUTRITION ON 
THE USE OF FLAVOPHOSPHOLIPOL IN FEEDINGSTUFFS FOR RABBITS 
Opinion expressed 27 April 1988 
TERMS OF REFERENCE (April 1982) 
The Scientific Committee for Animal Nutrition is requested to give an 
opinion on the following questions: 
1. Does the use of antibiotic flavophospholipol under the conditions 
proposed for feedingstuffs for rabbits (see background) result in the 
presence of residues in tissues and organs of the animal? If so, what 
is the qualitative and quantitative composition of these residues? 
Could these residues be harmful to the consumer? 
2. Could the excreted products, derived from the additive, be prejudicial 
to the environment? If so, what is the nature of the risks? 
3. In the light of the answers to the above questions, are the proposed 
conditions of use acceptable? 
BACKGROUND 
In accordance with the provisions of Council Directive 70/524/EEC of 
23 November 1970, concerning additives in feedingstuffs , as last 
(2) amended by Council Directive 88/228/EEC , the use of 
flavophospholipol is authorized at Community level under the conditions 
set out as follows in Annex I Section A of the Directive: 
(1) O.J. No L 270, 14.12.1970, p. 1 
(2) O.J. No L 101, 08.04.1988, p. 30 
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Species of animal 
: Turkeys 
: Other poultry, with the 
: exception of ducks, geese 
: laying hens and pigeons 
: Pigs 
: Piglets 
: Calves 
: Animals bred for fur 
: excluding rabbits 
: Laying hens 
: Cattle for fattening 
Maximum 
Age 
26 weeks 
16 weeks 
6 months 
3 months 
6 months 
6 months 
Minimum 
content 
Maximum : 
content : 
ppm (mg/kg) of : 
complete feedingstuff: 
1 
1 
1 
10 (*) 
6 
8 (*) 
2 
2 
2 (**) 
20 : 
20 : 
20 : 
25 (*) : 
16 : 
16 (*) : 
4 : 
5 : 
10 (**) : 
: (*) Milk replacers : 
: (**) The following statement must be notified in the : 
: instructions for use : "For supplementary feedingstuffs 
: the maximum dose in the daily ration must not exceed : 
: - for 100 kg bodyweight : 40 mg, : 
: - above 100 kg : add 1,5 mg for each additional : 
: 10 kg bodyweight" 
It is proposed to complete the authorization of use of this additive by 
the following provisions: 
Species of animal : rabbits 
Minimum and maximum content of complete feedingstuffs : 2-4 ppm (mg/kg) 
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OPINION OF THE COMMITTEE 
In its report of 22 January 1986 the Committee was of the opinion that 
the use of flavophospholipol under the conditions proposed (complete 
feedingstuffs for rabbits containing 2-4 mg/kg flavophospholipol) could 
be admitted provisionally. A reassessment of this use was envisaged when 
additional studies became available. 
At that time the Committee noted that the data submitted to it did not 
permit the conclusion that the product is not absorbed from the digestive 
tract of the rabbit. It requested further studies on tissue residues in 
this species using analytical methods other than microbiological assays. 
Subsequently further information on the metabolic balance and residues in 
rabbits was supplied, on which the Committee commented in its opinion 
dated 30th September 1986. In its comments the Committee considered the 
additional information supplied to be unsatisfactory because it still did 
not permit a definite conclusion that the product was not absorbed from 
the digestive tract and therefore could not lead to tissue residues in 
the rabbit, particularly if caecotrophy existed. The analytical 
methodology used specifically permitted only the microbiological 
identification of flavophospholipol but not of any possible 
microbiologically inactive metabolites. The Committee accepted that the 
use of an HPLC method would not offer any better approach to the 
determination of residues. It therefore requested a study in rabbits of 
the metabolism and pharmacokinetics of flavophospholipol appropriately 
labelled with 14-C under conditions comparing the effect of the presence 
and absence of caecotrophy. 
The Committee was eventually provided with additional documentation 
reporting the results of earlier preliminary experiments, carried out in 
1975-1976. In these the labelling of flavophospholipol with 14-C was 
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attempted biosynthetically and metabolic balance studies in rats with 
this material were subsequently carried out. Despite the low specific 
activity of the administered material these studies demonstrated that 
some 29% of the administered radioactivity was recovered as 14-C C0? 
and some 50% appeared in the faeces and urine. These results conflicted 
with the finding of 100% excretion of flavophospholipol in the faeces in 
a metabolic balance study which used a microbiological assay procedure. 
To clarify these discrepancies between apparent absorption and metabolism 
as shown in the experiment using labelled flavophospholipol, and apparent 
non-absorption as demonstrated in the experiments using microbiological 
activity measurements, the Committee was provided with additional 
information on the antibiotic activity of certain derivatives of 
flavophospholipol. It was shown that, when using a controlled chemical 
degradation of the molecule, the progressive removal of three of the 
glycosidic units did not change its specific antibiotic activity. 
Moreover, all the glycosidic units detached from 14-C-flavophospholipol 
were labelled. Even if such a chemical attack does not pretend to 
mimic the actual metabolism in the rabbit, the hypothesis may be 
reasonably put forward that such labelled fragments could be released 
in the digestive tract, especially in relation to the phenomenon of 
caecotrophy particular to this species, then absorbed and subsequently 
metabolized to 14-C0-,. 
The Committee therefore accepted, in the special case of the rabbit, that 
these findings largely explain the observed discrepancies. Taking into 
account the relatively inoccous nature of flavophospholipol and very 
low residue levels, it is of the opinion that flavophospholipol could 
be used safely at a minimum and maxium content of 2-4 mg/kg in complete 
feedingstuffs for rabbits. 
References : Dossiers supplied by Hoechst AG 
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REPORT OF THE SCIENTIFIC COMMITTEE FOR ANIMAL NUTRITION 
ON THE USE OF AVILAMYCIN IN FEEDINGSTUFFS FOR PIGS 
Opinion expressed 27 April 1988 
TERMS OF REFERENCE (July 1986) 
The Scientific Committee for Animal Nutrition is requested to give an 
opinion on the following questions: 
1. Has the use of the antibiotic avilamycin (oligosaccharide) at the 
dosages proposed for feedingstuffs for pigs (see background) 
significant effects on the growth? 
2. Is this use safe for the pig? 
3. Can it result in the development of resistance in bacteria to 
prophylactic or therapeutic preparations, or exert an effect on the 
persistance of Gram-negative bacteria in the digestive tract of the 
Pig? 
4. What is the metabolic fate of avilamycin in the pig? Does the 
proposed use result in residues in animal tissues? If so, what is the 
qualitative and quantitative composition of these residues? 
5. Do the toxicological studies allow to conclude that the proposed use 
does not present risks 
- for the consumer? 
- for the user? 
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6. What are the nature and the persistance of excreted products derived 
from avilamycin? Can these products be prejudicial to the environment? 
7. In the light of the answers to the above questions, are the proposed 
conditions of use acceptable? 
BACKGROUND 
Avilamycine was the subject of an application for admission in Annex II, 
Section A (Antibiotics), of Council Directive 70/524/EEC, of 23 November 
1970, concerning additives in feedingstuffs under the following 
conditions: 
Species of animal : pigs 
Dosages : - pigs up to 4 months : 40-80 mg/kg complete feedingstuff 
- pigs of 4 - 6 months : 20-40 mg/kg compete feedingstuff 
OPINION OF THE COMMITTEE 
1. Avilamycine is an oligosaccharide which consists of 12 identified and 
a small number of unidentified factors, of which factor A represents 
about 60%, factor Β about 7%, and factor D about 5%. The efficacy of 
avilamycin for promoting the growth of pigs has been tested in 
21 trials conducted in Europe and in 11 trials performed in the USA. 
These trials involved a total of 2508 animals. During these trials 
several batches of product from two different manufacturers were 
used. The parameters considered were the daily increase in live 
weight and the indices of food consumption and daily ingestion of 
avilamycine. 
The dose-response relationship was studied in a series of experiments 
consisting of 9 European trials with starter pigs with a live weight 
of 9 - 40 kg, 9 trials with pigs weighing 24 - 80 kg and using a 
(1) O.J. No L 270, 14.12.1970, p. 1 
- 14 
combination of the products of the two manufacturers, and three 
European bridging trials with the product of one manufacturer. Eight 
of the 11 US trials used one product and three the other product on 
pigs weighing between 23 and 70 kg. 
The composition of the feeds was very variable and often incompletely 
recorded. The protein content was frequently either above or below 
the norm and the energy values were never indicated. Evaluation of 
the carcases was frequently absent and the experimental protocol not 
always optimal. Most of the European feeding regimes included 100 -
125 mg/kg copper as well as avilamycine thus delivering two growth 
factors to the animals. This was done because of the current practice 
of adding copper to pig feed but it led to a considerable spread of 
the results. No attempts were made to demonstrate efficacy under 
different feeding conditions, although a 6% increase in body weight 
was demonstrated under optimal feeding conditions. The product was 
tested at the following concentrations: 0, 10, 20, 40, 60 and 80 mg 
avilamycine/kg final feed. 
Statistical treatment of the results using curvilinear regression 
methodology indicated that the optimum doses for fattening starter or 
grower pigs lay between 22 and 64 mg/kg feed. Doses of 40 mg/kg feed 
significantly improved the daily weight gain of starter pigs up to 
four months of age by about 5.6%. In grower pigs a significant 
improvement in weight gain was already noticeable at doses of 10 - 20 
mg/kg feed. Higher doses did not appear to show any further 
significant improvement in weight gain. The food conversion index was 
already significantly improved by 10 mg/kg feed, higher doses giving 
no better results. 
- 15 -
These findings suggest that avilamycin is effective for fattening pigs 
at doses of 20 - 40 mg/kg feed for pigs up to the age of four months 
and 10 - 20 mg/kg feed for pigs aged 4-6 months. 
2. Avilamycine administration to pigs at doses up to 3000 mg/kg feed 
caused no treatment-related adverse effects. It improved body weight 
gain significantly. Avilamycin is not toxic to cattle or sheep. 
Feeding of avilamycin has no effect on the quality of the pig meat as 
determined by taste panel tests. 
3. Avilamycine is an oligosaccharide consisting of several factors with a 
limited antibacterial spectrum. It is only effective against 
Gram-positive bacteria. In-vitro tests on various bacterial species 
showed only a slight reduction in sensitivity to avilamycin, 
Clostridia remaining fully sensitive. No correlation exists between a 
possible resistance to avilamycin and resistance to other 
therapeutically used antibiotics. Although high doses of avilamycin 
briefly increased the number of E. coli in the faeces, this effect 
disappeared after a few weeks. Salmonella-infected pigs showed no 
increased or prolonged faecal excretion of Salmonella when treated 
with avilamycin. 
The addition of avilamycine at the proposed doses to the feed of pigs 
does not lead to the development of bacterial resistance to 
prophylactic or therapeutic preparations nor does it cause a 
persistence of Gram-negative bacteria in the gut of pigs. 
4. The metabolic fate of avilamycin was studied using the compound 
uniformly labelled with 14-C on all constituent factors. Urinary 
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excretion was low (4.5%), most being excreted in the faeces (93.4%). 
There was only slight biliary excretion. Absorption was therefore 
minimal. Biotransformation yields two major metabolites of known 
structure. Excretion of avilamycin is very small, the major 
metabolites representing about 50% of the urinary and faecal excretion 
products. 
Tissue residues are minute at zero withdrawal time, the maximum 
residues in the liver reaching 0.14 - 0.22 mg/kg tissue (limit of 
detection 0.012 - 0.017 mg/kg tissue). Residues in the kidneys were 
0.10 mg/kg tissue, in the muscle 0.025 mg/kg tissue and there was 
slight accumulation in fat tissue. No residues with antibiotic 
activity were deteted in kidneys, muscle or fat by a radio-autographic 
method (limit of detection 50 ug/kg). No residues were detectable in 
muscle, liver, kidney and body fat after five days withdrawal. The 
residues are essentially inactive antimicrobially. 
5. Avilamycin has been tested thoroughly in the mouse and rat in 
short-term, long-term, multigeneration-reproduction and teratology 
studies and in a relay toxicity study in rats without revealing any 
carcinogenic, mutagenic or reproductive effects. A 12-months study in 
dogs showed no significant toxic effects. However, doses of 
3000 mg/kg feed of avilamycin activity, administered to rats in the 
multigeneration-reproduction study, caused borderline hepatic 
enlargement in some of the progeny in both sexes without any 
associated clinico-chemical or histological abnormalities. The 
substance is not genotoxic when examined in an adequate battery of 
mutagenicity tests. It has no allergenic potential but is slightly 
irritant to skin, eyes and the respiratory tract. The NEL is based on 
multigeneration-reproduction study. The ADI is estimated to be 
0.15 mg/kg body weight avilamycin activity. 
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On the basis of these findings the Committee concludes, that at the 
doses proposed for use in pigs there is no risk for the consumer nor 
for the user. 
6. Avilamycine has been studied extensively for persistence of excreted 
products in the environment. Only 5% of the excreted products are 
avilamycins, the remainder being hydrolysis products of which 50% are 
the two major metabolites. Avilamycin is not very stable in soil or 
water and is broken down within one day in sunlight. These factors 
suggest that it is unlikely to accumulate in the environment. 
It is poorly soluble in water and has a low n-octanol/water partition 
coefficient suggesting little or no risk of avilamycin passing from 
soil to water or to any life forms on land and in water. Its toxicity 
to Daphnia, fish and earthworms is small. 
The excreta of pigs given avilamycin do not affect methanogenesis or 
soil nitrification when used as manure nor do they have any 
deleterious effects on plant crops. 
In the opinion of the Committee the excreted products derived from 
avilamycine are not prejudicial to the environment. 
7. The chemical composition of avilamycin is controlled by HPLC and its 
potency is standardised microbiologically. The range of factors used 
in the efficacy trials is about the same as that in the present 
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production. For official control microbiological tests are 
recommended. 
8. In the light of the information supplied, the Committee is of the 
opinion that avilamycine may be used in the feedingstuff for pigs 
without risk at the following concentrations: 
- pigs up to four months : 20 to 40 mg/kg complete feedingstuff 
- pigs of 4 - 6 months : 10 to 20 mg/kg complete feedingstuff. 
References : Dossier of Eli Lilly & Co 
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SECOND REPORT OF THE SCIENTIFIC COMMITTEE FOR ANIMAL NUTRITION ON 
THE USE OF VIRGINIAMYCIN IN FEEDINGSTUFFS 
FOR FATTENING CATTLE 
Opinion expressed 27 April 1988 
TERMS OF REFERENCE (July 1986) 
The Scientific Committee for Animal Nutrition is requested to give an 
opinion on the following questions: 
1. Has the use of the antibiotic virginiamycin at the dosages proposed 
for feedingstuffs for fattening cattle (see BACKGROUND) significant 
effects on the growth? 
2. Can this use result in the development of resistance in bacteria to 
prophylactic or therapeutic preparations or exert an effect on the 
persistence of gram-negative bacteria in the digestive tract of 
bovines? 
3. What is the metabolic rate of virginiamycin in bovines? Does the 
proposed use result in animal tissues? If so, what is the qualitative 
and quantitative composition of these residues? 
4. Do the toxicological studies of the product allow to conclude that the 
proposed use does not present risks: 
- for the consumer? 
- for the user? 
5. What are the nature and the persistence of the excreted products 
derived from virginiamycin? Can these products be prejudicial to the 
environment? 
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6. In the light of the answers to the above questions, are the proposed 
conditions of use acceptable? 
BACKGROUND 
In accordance with the provisions of Council Directive 70/524/EEC of 
23 November 1970 concerning additives in feedingstuffs(l), as last 
amended by the Commission Directive 88/228/EEC(2), the use of 
virginiamycin is authorized under the conditions set out as follows in 
the Annexes to the Directive: 
Species of animal 
: Turkeys (up to 26 weeks) 
: Other poultry, excluding 
: ducks, geese, laying hens and 
: pigeons 
: (up to 16 weeks) 
: Piglets (up to 4 months) 
: Pigs (up to 6 months) 
: Calves (up to 16 weeks) 
: Calves (up to 6 months) 
: Laying hens** 
Minimum content Maximum content : 
mg/kg of complete feedingstuff : 
5 
5 
5 
5 
5 
5 
10 
20 : 
20 : 
50 : 
20 : 
50 : 
20 : 
80* : 
20 : 
An extension of the use of virginiamycin under the following 
conditions has been requested: 
Species of animal : fattening cattle 
Dosages : - in complete feedingstuffs : 15-50 mg/kg 
- in the daily ration : 150 mg/100 kg live weight 
+ 6 mg for each 10 kg live weight exceeding 100 kg. 
* milk replacers 
** authorized by derogation up to 30 November 1988 (Annex II) 
(1) O.J. No L 270, 14.12.1970, p. 1 
(2) O.J. No L 101, 08.04.1988, p. 30 
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OPINION OF THE COMMITTEE 
1. The efficacy of virginiamycin for fattening cattle has been tested in 
22 trials involving 1852 animals. These trials were conducted in the 
USA and several European countries on cattle of various breeds and 
baseline weights, for different lengths of time and under different 
feeding regimes, energy intakes and climatic conditions. 
The dose/response relationship was studied over a range of doses (5, 
10, 15, 25, 40 and 50 mg/kg complete feedingstuff) equivalent to doses 
of 0,2-1,2 mg/kg liveweight/day or 60-500 mg/animal/day. The results 
show that, at doses between 10 and 50 mg/kg feedingstuff, the addition 
of virginiamycin significantly improves the daily liveweight gain and 
the feed conversion ratio. The dose/response relationship is 
curvilinear. A largescale trial on 800 animals showed that the 
carcase weight at slaughter (hot carcase weight) increases with dose 
and that carcase quality is not affected. 
These findings show that the minimum and maximum levels proposed are 
appropriate. 
To prevent incorrect use of supplemented feed in ruminating cattle it 
is advisable to fix a maximum daily dose of virginiamycin for each 
animal in relation to body weight. As feed intake in ruminating 
cattle does not increase in proportion to body weight, it is necessary 
to adjust the quantity of virginiamycin in the ration according to the 
formula: 90 mg + 80 mg/100 kg b.w. as set out in the table below: 
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: Animal 
: weight 
: (kg) 
: 100 
: 150 
: 200 
: 250 
: 300 
: 350 
: 400 
: 450 
: 500 
: 550 
: 600 
Average 
daily feed 
intake 
(kg) 
3,4 
4,4 
5,6 
6,7 
7,6 
8,3 
9,0 
9,6 
10,4 
10,5 
10,9 
Virginiamycin 
mg/head/day 
90 mg + 80 mg/100 kg 
b.w. 
170 
210 
250 
290 
330 
370 
410 
450 
490 
530 
560 
Equivalent in mg 
of virginiamycin/kg : 
complete feedingstuff: 
50 : 
47,7 : 
44,6 
43,3 : 
43,4 : 
44,6 
45,5 : 
46,8 : 
47,1 : 
50 : 
51,3 : 
2. The antibacterial properties of virginiamycin and the question of the 
development of resistance by organisms within the spectrum of activity 
of this substance have been investigated repeatedly because this 
antibiotic has been used for several years already as a feed additive 
for other farm animals, e.g. pigs, calves, laying poultry. The fact 
that the antibiotic consists of two separate antimicrobially active 
substances probably explains why there has been no increase in the 
resistance levels of Gram-positive bacterial species against this 
antibiotic and no change in the sensitivity to antibiotics used under 
clinical conditions for the treatment and the prevention of infectious 
diseases. 
An additional study was carried out on fattening cattle to ascertain 
the influence of virginiamycin on the Gram-negative intestinal 
bacterial flora (E. coli, Salmonellae). It showed that there was no 
significant increase in the bacterial counts of E. coli either in the 
jejunum and ileum or in the faeces of treated animals compared to 
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controls, when doses of 65 ppm and 80 ppm were used in the fattening 
period. It may be concluded therefore, that the inclusion of 
virginiamycin in feedingstuffs at the proposed levels does not favour 
the growth of salmonella and does not result in persistence and 
increased excretion of Gram-negative bacteria in the faeces of 
fattening cattle. 
Metabolic studies in rats with 14-C-labelled virginiamycin showed 
rapid excretion of radioactivity, only 15% being absorbed from the 
gut. 80% of the blood radioactivity was found in the plasma, of which 
75% was protein-bound. Radioactivity was also present in liver, lung 
and muscle. In adult male cattle 93.6% of radioactivity is excreted 
rapidly in the faeces over 120 hours and 1.3% in the urine over 
72 hours. Radioactivity is excreted in the bile only for 72 hours 
which confirms the absence of significant enterohepatic cycling. 
Overall there is very little absorption of virginamycin from the gut 
in cattle. 
In vitro studies have shown that only factor M is partially 
metabolised in the rumen into 3 major metabolites. Two are reduction 
products from bacterial action and inactive antibiotically. The third 
has about 50% of the antibiotic activity of factor M. Animals treated 
orally for 7 days with 1 mg/kg body weight of 14-C-labelled 
virginiamycin had no detectable residues in muscle and fat at zero 
withdrawal time (limit of detection: 50 ug/kg and 250 ug/kg 
respectively). Residues in the liver and kidneys decreased with a 
half-life of 5 days to 0,24 and 0,11 mg/kg tissue after 120 hours. 
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No tissue residues were detectable microbiologically (limit of 
detection 50 ug/kg). 
40 % of the radioactive residues in the liver are extractable. They 
consist essentially of numerous metabolites, none exceeding 6.5% of 
the total radio-activity. Their nature has not been determined. The 
non-extractable liver residues are associated with the protein 
fraction. Rats and cattle metabolise virginiamycin similarly. The 
presence of 14-C-labelled cholesterol indicates that some of the 
virginiamycin is metabolised to acetate which latter is then used in 
the synthesis of cholesterol. The non-extractable fraction yields on 
hydrolysis 3 components of factor M. The contribution of specific 
amino acids from hydrolysis of factor S is very small. 
The acute oral toxicity of virginiamycin is low in rats and mice, the 
LD,.« being greater than 7000 mg/kg body weight. No adverse effects 
were noted in 90-day studies in rats and dogs given doses from 5 to 
100 mg/kg body weight. Studies of similar length in pigs with doses 
up to 500 mg/kg body weight and in calves up to 80 mg/kg body weight 
showed no toxic effects. The NEL in a 6-months study in dogs given 
25,200 or 750 mg/kg body weight was 25 mg/kg body weight. Higher 
doses caused lower erythrocyte counts, an increase in relative kidney 
weight and only at the highest dose bile duct proliferation. 
An oral study extending over 2.5 years in rats with doses of 25, 50 
and 250 mg/kg body weight per day established an NEL of 25 mg/kg body 
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weight. At higher levels there were changes in haematological 
parameters and testicular weights were increased. There was no 
evidence of carcinogenicity. A 2-year feeding study in mice with 
doses of 25, 75 and 1000 mg/kg body weight per day showed increased 
incidences of malignant lymphoma in males and endometrial stromal 
sarcomas in females. However these incidences were within the range 
of historical controls and were therefore not considered to be 
treatment related. The NEL in this study was 25 mg/kg body weight. 
Higher levels showed increased food intakes in males and increased 
kidney weights in females. This study also revealed no evidence of 
carcinogenicy. From these long-term studies an ADI of 0.25 mg/kg body 
weight/day may be established. 
No adverse effects on reproduction were noted in 1-generation 
reproduction studies in rats, rabbits and pigs fed virginiamycin from 
mating to delivery with doses up to 500 mg/kg body weight in rats and 
20 or 100 mg/kg feed in rabbits and pigs. The NEL of a 2-generation 
reproduction study in rats was 65 mg/kg body weight. Higher doses 
caused a reduction in pup weight of the F_. generation during 
lactation. Teratogenicity studies in mice showed an NEL of 160 mg/kg 
body weight and in rats of 75 mg/kg body weight. Higher doses were 
toxic to the dams but caused no embryotoxicity or teratogenicity. 
In vitro mutagenicity tests in various strains of Salmonella 
typhimurium were negative. However the mouse lymphoma test was 
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positive. An in vitro test for Unscheduled DNA Synthesis in rat 
primary hepatocytes was negative. An in vitro SCE test was negative 
as well. 
Only 2 cases of dermal allergy to virginiamycin in at least 60 
chronically exposed workers have been reported during 20 years of 
production. No animal tests to establish irritancy and sensitization 
potential have been carried out. 
The toxicological data establish an ADI of 0.25 mg/kg body weight and 
suggest the absence of any health hazard to the consumer from any 
residues of virginiamycin. 
5. Many studies have been carried out on the environmental impact of the 
use of virginiamycin. Most of the substance present in excreted 
products is the unaltered compound and about 20% is present as the 
three metabolites of factor M in approximately equal proportions. 
Virginiamycin is unstable in the environment and disappears quickly 
from excreta, soil and water. Its half-life is 24 hours. It is very 
slightly toxic to land and aquatic animals and plants. Trials 
conducted with cattle slurry containing 1.2 - 150 mg/kg virginiamycin 
have shown no deleterious effects on methanogenesis. Contamination of 
the environment would appear unlikely on the basis of these data. 
6. For the reasons set out above the Committee is of the opinion that the 
use of virginiamycin in feedingstuffs for cattle at the dosages 
proposed is acceptable. 
References : Dossier from Smith-Kline Animal Health Products (1986) 
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REPORT OF THE SCIENTIFIC COMMITTEE FOR ANIMAL NUTRITION ON THE 
USE OF ASTAXANTHIN IN FEEDINGSTUFFS FOR SALMON AND TROUT 
Opinion expressed 8 March 1989 
TERMS OF REFERENCE (June 1985) 
The Scientific Committee for Animal Nutrition is requested to give an 
opinion on the following questions : 
1. Does the use of astaxanthin at the level of 100 mg/kg of complete 
feedingstuff result in effects on the fish other than the pigmenta-
tion of the muscle and skin ? 
2. Does the desired pigmentation need the use of 100 mg astaxanthin/kg 
complete feedingstuff throughout the rearing period ? 
3. Is the proposed use safe for the target species ? 
4. Is the proposed use safe for the consumer ? Which is the qualitative 
and quantitative composition of astaxanthin residues in edible 
tissues and organs of the fish ? 
BACKGROUND 
It is necessary to establish whether the use of astaxanthin under the 
proposed conditions is in conformity with the requirements of Council 
Directive 70/524/EEC of 23 November 1970 concerning additives in 
feedingstuffs (1) (2). 
(1) O.J. No. L 270 of 14.12.1970. p. 1 
(2) O.J. No. L 319 of 8.12.1984, p. 12 
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OPINION OF THE COMMITTEE 
1. Many species of crustácea and fish contain carotenoids naturally in 
their muscle and skin. However, only certain salmonid species have 
pigmented muscle. Astaxanthin is the major carotenoid of wild 
Atlantic salmon, while other salmonids may utilisé a wider range of 
carotenoids. Free astaxanthin and its isomers have been identified 
in the muscle of many sea and fresh water species of salmon. The 
carotenoids in the skin are usually esterifièd. The source of all 
carotenoids in muscle and skin of salmonids is their food as the 
carotenoids cannot be synthesised by the fish. It is therefore 
necessary to add astaxanthin to salmon and trout feedingstuffs, when 
the fish are reared in fish farms to replace the natural sources. 
Astaxanthin occurs in the muscle of wild salmon and trout at levels 
: up to 35 mg/kg. Because astaxanthin is the natural pigment in the 
muscle and skin of salmon and trout at levels higher than can be 
induced by feedingstuffs containing 200 mg/kg it cannot result in 
unforeseen biological effects. 
2. The incorporation of 20-100 mg astaxanthin/kg complete feedingstuff 
over 15 days yields a level in the muscle of farmed salmon and trout 
of 3 and 8 mg/kg muscle respectively. 200 mg/kg feedingstuff produce 
about 10 mg/kg muscle and 400 mg/kg feedingstuff about 15 mg/kg 
muscle. To achieve a desirable colouring of the muscle, doses of 
20 to 100 mg astaxanthin/kg complete feedingstuff need to be 
administered during the greater part óf the growing period. 
3. The data supplied show that astaxanthin is safe for salmonids. It may 
contribute to the development of fish and crustaceans and be 
involved in the physiology of the reproductive functions, like mating 
behaviour, stimulation of spermatozoa, protection of eggs against 
light etc. In a recent publication it has been reported that 
astaxanthin has a favourable effect on the immune réponse (3). 
(3) Bendich, A. and Shapiro, S.S.. J. Nutrition, 116, 2254-2262, 1986 
Al-Kalifa, Α., Simpson, K.L., Comp. Biochem. Physiol.B. Comp. 
Biochem., 91_ B, 563-568, 1988 
Dossier from Hoffman-La Roche 1986 
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Astaxanthin has a low acute toxicity, the oral LD-50 being over 2000 
mg/kg in the rat. A 14-week study in rats with doses of 300, 600 and 
1200 mg/kg b.w. showed slight hepatotoxicity at the higher levels and 
some nephrotoxicity at.the highest dose. The NEL was 300 mg/kg b.w. 
A 13-week study in dogs with doses of 40, 75 and 160 mg/kg b.w. 
showed no adverse effects. 
A one generation reproduction study in rats with doses of 25, 100 and 
400 mg/kg b.w./day showed no adverse effects on reproductive function. 
Litter parameters and pup development were normal except for a higher 
pup mortality during lactation at the highest dose level. The NEL was 
100 mg/kg b.w. Embryotoxicity and teratogenicity studies in rats with 
doses of 250, 500 and 1000 mg/kg b.w. and in rabbits with 100, 200, 
and 400 mg/kg b.w. showed no adverse effects. There was no evidence 
of genotoxic potential in mutagenicity tests in Salmonella 
typhimurium and a micronucleus test in the mouse. 
Because of the observation that moderately elevated doses of can-
thaxantin, a structurally closely related carotenoid, may cause 
retinal deposits of the carotenoid in the human retina, comparative 
studies on the metabolism and the pharmaco-kinetics of astaxanthin 
were carried out in the rat and man. Initial plasma levels of 
14-C-labelled astaxanthin were much lower over the first 6 hours than 
those of equivalently dosed canthaxanthin but were subsequently 
similar. Canthaxanthin levels in the liver and spleen were much 
higher compared to astaxanthin, the highest levels of which were found 
in the small intestine. All other tissue levels remained comparable. 
Following a single oral administration only 10%. was apparently 
absorbed, the remainder appearing in the faeces or gut contents, Of 
the absorbed astaxanthin some 66% appears in the urine, about 9% in 
the liver, about 7% in the gut and about 16% in the carcase. 
Astaxanthin is metabolised and excreted more quickly than canthaxanthin. 
About 10% of astaxanthin in feedingstuff is absorbed by fish, the 
proportion of isomers in the muscle matching that in the diet. No 
metabolism occurs in the muscle of fish but in the skin a small 
percentage is metabolised to zeaxanthin and other carotenoids. 
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Administration of 100 mg astaxanthin or canthaxanthin to a human 
volunteer resulted in almost 4 times higher peak plasma levels of 
canthaxanthin which would be equivalent to 7 kg fish containing 13 mg/kg 
astaxanthin. Astaxanthin was almost completely eliminated from the 
plasma after 48 hours while canthaxanthin levels had reduced to 50% only. 
After multiple administration the elimination half-time was about 17 
hours for astaxanthin compared to 4.5 days for canthaxanthin. To reach 
similar steady-state plasma levels would require doses of astaxanthin 
25 times higher than cantaxanthin. 
The toxicity and pharmaco-kinetic data do not provide any evidence for a 
hazard to the consumer from the consumption of salmon or trout which 
had been fed up to 200 mg astaxanthin/kg complete feedingstuff. At this 
level of addition, the amount of astaxanthin appearing in the muscle 
of fish is about half that found in wild species. The question of 
residues or withdrawal periods therefore does not arise. The differences 
in the parmaco-kinetics of astaxanthin and canthaxanthin suggest that 
these compounds are metabolised differently by man. In addition man 
excretes astaxanthin much more rapidly so that retinal deposition of 
astaxanthin after consumption of pigmented fish muscle is unlikely. 
The use of astaxanthin up to 100 mg/kg complete feedingstuff is therefore 
acceptable in the opinion of the Committee. 
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Report of the Scientific Committee for Animal Nutrition 
on the use of Nitrovin in feedingstuffs 
Opinion expressed 29/30 November 1988 
TERMS OF REFERENCE (November 1988) 
The Scientific Committee for Animal Nutrition (SCAN) is requested to 
give an opinion on the following question: 
- Does the use of nitrovin as a growth promoter under the conditions 
given in the background give rise to dangers for human or animal 
health, particularly mutagenic, teratogenic or cancerogenic effects 
or present undesirable effects on the environment? 
BACKGROUND 
In accordance with the provisions of Council Directive 70/524/EEC (1) 
of 23 November 1970, concerning additives in feedingstuffs, Member 
States are authorized to use, by way of derogation up to 30 June 1989, 
nitrovin as an additive in feedingstuffs for use as a growth promoter 
in chickens for fattening, other poultry, calves and pigs under the 
following conditions: 
(1) OJ. no. L 270, 14.12.1970, p. 1. 
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: Additive 
: l.Growth-
: promoters 
: Nitrovin 
: Species or 
: category 
: of animal 
Chickens for 
fattening 
Turkeys 
Other poul-
try except 
ducks,geese, 
laying hens, 
pigeons 
Calves : 
Piglets : 
Pigs for : 
fattening : 
: Maximum 
: age 
-
26 weeks 
16 weeks 
6 month : 
10 weeks : 
6 month : 
: Min. : Max. 
: content : content 
: mg/kg of 
: complete 
: feedingstuffs 
10 
10 
10 
20 : 
40 : 
10 : 
20 : 
5 : 
15 
15 
15 
40 : 
80 : 
25 : 
30 : 
15 : 
: Other : 
: provisions : 
: For all feed-: 
: ingstuffs : 
: mixing or : 
: simultaneous : 
: use with : 
. antibiotics : 
prohibited : 
Milk re- : 
placers only : 
Milk re- : 
placers only : 
Nitrovin had been authorized, in Annex I of the 4th Commission 
Directive 74/38/EEC (2) amending the annexes to Council Directive 
70/524/EEC (1) as a growth promoter for chickens for fattening and in 
Annex II for pigs, calves and turkeys. In 1976 the Annex II uses for 
pigs were transferred to Annex I (13th Commission Directive 76/13/EEC 
(3)). 
(2) OJ no. L 30, 17.12.1974, p. 21 
(3) OJ no. L 4, 09.01.1976, p. 21 
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Subsequently evidence arose of an apparant lack of stability 
transferred back to Annex II (46th Commission Directive 84/349/EEC 
(4)), whilst further work relating to stability was carried out. This 
work showed that the apparent lack of stability was due to the 
unreliability of the method of analysis then being used. A 
satisfactory method has now been developed resolving this problem 
(Dossiers Orphahell). 
More recently doubts have been raised by certain Member States, partly 
based on a IARC publication of 1983, concerning the safety of the 
substance, in particular carcinogenicity, mutagenicity, teratogenicity 
and hazards for the environment. Data not previously known to the 
Commission have now become available. 
OPINION OF THE COMMITTEE 
The SCAN was provided with comprehensive documentation on nitrovin 
(see annex). In evaluating this evidence the working group noted that 
the data on metabolism in rats, pigs and chickens (Dossier Cyanamide) 
were adequate. Nitrovin is poorly absorbed (max. 1%), most being 
excreted in the faeces. 
The available short-term studies in rat, dog and pig (Dossier 
Cyanamide) showed some evidence of hepatotoxicity and adverse effects 
on the kidneys and intestinal tract. From these a no-effect level of 
about 12,5 mg/kg body weight could be estimated. 
(4) OJ. no. L 183, 11.07.1984, p. 15 
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Chronic studies were available in three species: 
The two chronic studies in rats (Dossier Cyanamide) were negative with 
regard to carcinogenicity. Both were inadequate regarding the number 
of animals, the parameters investigated and the duration of the 
studies. 
The chronic study in hamsters (Dossier Cyanamide) showed no evidence 
of carcinogenic activity. 
Of three chronic studies in mice, the study in C 57 black mice 
(Dossier Cyanamide) showed no evidence of carcinogenicity. The other 
two studies (Dossier Cyanamide) were performed in a lung-adenoma 
susceptible strain. Both showed an increased response to nitrovin 
administration which was dose-related concerning frequency, size and 
malignancy of tumors, particularly in females. However, the results 
of investigations in these susceptible strains are difficult to 
interpret. A whole series of mutagenicity tests, in bacterial systems 
and a test for sex-linked recessive lethals in Drosophila were 
positive, being evidence of a genotoxic potential of nitrovin. 
The SCAN is of the opinion that information on the following aspects 
is required to enable a full toxicological evaluation to be made: 
1. in vivo mutagenicity tests, particularly for their chromosomal 
effects 
2. adequate multigeneration-reproduction and teratogenicity studies 
3. adequate investigations of environmental impact. 
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For evaluating potential hazards to the user, additional information 
is needed on dust formation and whether an antidust formulation can be 
provided. 
To evaluate the hazards to the consumer a better analytical method for 
tissue residues with a sensitivity of 10 ppb or less is needed. The 
SCAN draws attention to the fact that the apparent no-effect level in 
the rat and dog study would allow the establishment of an acceptable 
daily intake ( A D D of approximately 125 ug/kg bw. This is very close 
to the limit of sensitivity of the presently available method of 
analysis. In order to determine whether the ADI is likely to be 
exceeded, a much more sensitive method of analysis is required. 
Furthermore additional residue studies using such a more sensitive 
method are required. 
On the basis of the information hitherto available the SCAN is unable 
to give a final opinion on the hazard for humans and target species, 
particularly the carcinogenic, mutagenic and teratogenic potential of 
nitrovin and on the possible hazards to the environment. Nevertheless 
the Committee wishes to draw attention to the advice given on the 
Nitrofuranes published in 1979. 
REFERENCES 
Dossiers Cyanamide international corporation (1971-1976) 
Dossiers Orphahell (1985-1987) 
IARC - Monograph 31 (1983), Lyon Symposium 
Reports of the Scientific Committee for Animal Nutrition, first 
series, Brussels 1979. 
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